Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00261
|
|||||
| Drug Name |
Lenalidomide
|
|||||
| Synonyms |
3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; ALBB-015321; CC 5013; CC-5013; CC-5013, Revlimid, Lenalidomide; CC5013; CDC 501; CDC-501; CDC-5013; Celgene brand of lenalidomide; ENMD-0997; IMID-5013; IMiD3; IMiD3cpd; Lenalidomide (Immunomodulator); Lenalidomide (USAN/INN); Lenalidomide [USAN]; Revamid; Revimid; Revlimid; Revlimid (Celgene); Revlimid (TN); Thalidomide analog CC-5013
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Anaemia [ICD11: 3A9Z] | Approved | [1] | |||
| Multiple myeloma [ICD11: 2A83] | Approved | [1] | ||||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C13H13N3O3
|
|||||
| Canonical SMILES |
C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
|
|||||
| InChI |
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
|
|||||
| InChIKey |
GOTYRUGSSMKFNF-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 191732-72-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 259.26 | Topological Polar Surface Area | 92.5 | ||
| Heavy Atom Count | 19 | Rotatable Bond Count | 1 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
-0.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103222228
, 109693476
, 113461419
, 117883377
, 119509589
, 12015317
, 124409664
, 124756946
, 124893327
, 124893328
, 125163752
, 125343917
, 126591352
, 126628313
, 126652519
, 126667069
, 127984536
, 134338492
, 134964412
, 135134887
, 135600354
, 135610831
, 135683667
, 136367898
, 136374703
, 136949134
, 137000301
, 137039885
, 140119412
, 143496160
, 144116136
, 144206045
, 14847985
, 152237735
, 152258939
, 160647784
, 30420059
, 46505725
, 47206522
, 50067858
, 50112744
, 50484855
, 53786789
, 57399776
, 81092908
, 85174578
, 91148448
, 92719197
, 9372858
, 99437218
|
|||||
| ChEBI ID |
ChEBI:63791
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Lenalidomide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB00480) | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.